TY - JOUR
T1 - Higher Preoperative Maximum Standardised Uptake Values (SUVmax) Are Associated with Higher Biochemical Recurrence Rates after Robot-Assisted Radical Prostatectomy for [68Ga]Ga-PSMA-11 and [18F]DCFPyL Positron Emission Tomography/Computed Tomography
AU - de Bie, Katelijne C. C.
AU - Veerman, Hans
AU - Bodar, Yves J. L.
AU - Meijer, Dennie
AU - van Leeuwen, Pim J.
AU - van der Poel, Henk G.
AU - Donswijk, Maarten L.
AU - Vis, André N.
AU - Oprea-Lager, Daniela E.
N1 - Publisher Copyright: © 2023 by the authors.
PY - 2023/7/1
Y1 - 2023/7/1
N2 - This study aimed to investigate the association between the 68Ga- or 18F-radiolabeled prostate-specific membrane antigen (PSMA) tracer expression, represented by the maximum standardised uptake value (SUV max) of the dominant intraprostatic lesion, and biochemical recurrence (BCR) in primary prostate cancer (PCa) patients prior to robot-assisted radical prostatectomy (RARP). This was a retrospective, multi-centre cohort study of 446 patients who underwent [ 68Ga]Ga-PSMA-11 (n = 238) or [ 18F]DCFPyL (n = 206) Positron Emission Tomography/Computed Tomography (PET/CT) imaging prior to RARP. SUV max was measured in the dominant intraprostatic PCa lesions. [ 18F]DCFPyL patients were scanned 60 ([ 18F]DCFPyL-60; n = 106) or 120 ([ 18F]DCFPyL-120; n = 120) minutes post-injection of a radiotracer and were analysed separately. To normalise the data, SUV max was log transformed for further analyses. During a median follow-up of 24 months, 141 (30.4%) patients experienced BCR. Log 2SUV max was a significant predictor for BCR (p < 0.001). In the multivariable analysis accounting for these preoperative variables: initial prostate-specific antigen (PSA), radiologic tumour stage (mT), the biopsy International Society of Urological Pathology grade group (bISUP) and the prostate imaging and reporting data system (PI-RADS), Log 2SUV max was found to be an independent predictor for BCR in [ 68Ga]Ga-PSMA-11 (HR 1.32, p = 0.04) and [ 18F]DCFPyL-120 PET/CT scans (HR 1.55, p = 0.04), but not in [ 18F]DCFPyL-60 ones (HR 0.92, p = 0.72). The PSMA expression of the dominant intraprostatic lesion proved to be an independent predictor for BCR in patients with primary PCa who underwent [ 68Ga]Ga-PSMA-11 or [ 18F]DCFPyL-120 PET/CT scans, but not in those who underwent [ 18F]DCFPyL-60 PET/CT scans.
AB - This study aimed to investigate the association between the 68Ga- or 18F-radiolabeled prostate-specific membrane antigen (PSMA) tracer expression, represented by the maximum standardised uptake value (SUV max) of the dominant intraprostatic lesion, and biochemical recurrence (BCR) in primary prostate cancer (PCa) patients prior to robot-assisted radical prostatectomy (RARP). This was a retrospective, multi-centre cohort study of 446 patients who underwent [ 68Ga]Ga-PSMA-11 (n = 238) or [ 18F]DCFPyL (n = 206) Positron Emission Tomography/Computed Tomography (PET/CT) imaging prior to RARP. SUV max was measured in the dominant intraprostatic PCa lesions. [ 18F]DCFPyL patients were scanned 60 ([ 18F]DCFPyL-60; n = 106) or 120 ([ 18F]DCFPyL-120; n = 120) minutes post-injection of a radiotracer and were analysed separately. To normalise the data, SUV max was log transformed for further analyses. During a median follow-up of 24 months, 141 (30.4%) patients experienced BCR. Log 2SUV max was a significant predictor for BCR (p < 0.001). In the multivariable analysis accounting for these preoperative variables: initial prostate-specific antigen (PSA), radiologic tumour stage (mT), the biopsy International Society of Urological Pathology grade group (bISUP) and the prostate imaging and reporting data system (PI-RADS), Log 2SUV max was found to be an independent predictor for BCR in [ 68Ga]Ga-PSMA-11 (HR 1.32, p = 0.04) and [ 18F]DCFPyL-120 PET/CT scans (HR 1.55, p = 0.04), but not in [ 18F]DCFPyL-60 ones (HR 0.92, p = 0.72). The PSMA expression of the dominant intraprostatic lesion proved to be an independent predictor for BCR in patients with primary PCa who underwent [ 68Ga]Ga-PSMA-11 or [ 18F]DCFPyL-120 PET/CT scans, but not in those who underwent [ 18F]DCFPyL-60 PET/CT scans.
KW - PET/CT
KW - [ F]DCFPyL
KW - [ Ga]Ga-PSMA-11
KW - [F]DCFPyL
KW - [Ga]Ga-PSMA-11
KW - biochemical recurrence
KW - prostate cancer
KW - standardised uptake value
UR - http://www.scopus.com/inward/record.url?scp=85167466820&partnerID=8YFLogxK
U2 - https://doi.org/10.3390/diagnostics13142343
DO - https://doi.org/10.3390/diagnostics13142343
M3 - Article
C2 - 37510087
SN - 2075-4418
VL - 13
JO - Diagnostics (Basel, Switzerland)
JF - Diagnostics (Basel, Switzerland)
IS - 14
M1 - 2343
ER -